While the reduction in price target could suggest a more conservative outlook on Humana's future stock performance, the maintenance of a Buy rating indicates that Goldman Sachs still sees positive potential in the stock. The impact is likely neutral in the short term as the lowered price target may balance out the positive sentiment of the Buy rating.